"Acetylcysteine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
| Descriptor ID |
D000111
|
| MeSH Number(s) |
D02.886.030.230.259 D12.125.166.230.259
|
| Concept/Terms |
Acetylcysteine- Acetylcysteine
- N-Acetyl-L-cysteine
- N Acetyl L cysteine
- N-Acetylcysteine
- N Acetylcysteine
- Mercapturic Acid
- Acid, Mercapturic
Acetylcysteine Sodium- Acetylcysteine Sodium
- Sodium, Acetylcysteine
- Acetylcysteine, Monosodium Salt
- Monosodium Salt Acetylcysteine
Fluprowit- Fluprowit
- Optipect Hustengetränk
- Hustengetränk, Optipect
- Muco Sanigen
- Sanigen, Muco
|
Below are MeSH descriptors whose meaning is more general than "Acetylcysteine".
Below are MeSH descriptors whose meaning is more specific than "Acetylcysteine".
This graph shows the total number of publications written about "Acetylcysteine" by people in this website by year, and whether "Acetylcysteine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 4 | 5 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 5 | 7 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 3 | 4 |
| 2007 | 2 | 5 | 7 |
| 2008 | 5 | 3 | 8 |
| 2009 | 1 | 3 | 4 |
| 2010 | 0 | 9 | 9 |
| 2012 | 2 | 3 | 5 |
| 2013 | 4 | 2 | 6 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acetylcysteine" by people in Profiles.
-
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023 01 26; 78(1):75-89.
-
Genotypic and phenotypic spectrum of infantile liver failure due to pathogenic TRMU variants. Genet Med. 2023 06; 25(6):100314.
-
GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage. Nutrients. 2022 Mar 07; 14(5).
-
GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition: Implications for Healthy Aging. J Nutr. 2021 12 03; 151(12):3606-3616.
-
Supplementing glycine and N-acetylcysteine (GlyNAC) rapidly improves health-related quality of life and lowers perception of fatigue in patients with HIV. AIDS. 2021 07 15; 35(9):1522-1524.
-
Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway. PLoS One. 2021; 16(5):e0252541.
-
Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clin Transl Med. 2021 03; 11(3):e372.
-
TRMU deficiency: A broad clinical spectrum responsive to cysteine supplementation. Mol Genet Metab. 2021 02; 132(2):146-153.
-
Response to Comment on Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic. Clin Toxicol (Phila). 2021 01; 59(1):78-79.
-
Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic. Clin Toxicol (Phila). 2021 01; 59(1):69.